ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
M

ASH 2021 Update on the Safety and Efficacy of CD37-Targeting Naratuximab Emtansine + Rituximab in DLBCL and Other NHLs: A Phase 2 Study

By ASH 2021 Conference Coverage on VuMedi FEATURING Moshe Y. Levy
By ASH 2021 Conference Coverage on VuMedi FEATURING Moshe Y. Levy
111 views
January 4, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
Lymphoma
05:05
ASH 2021 Conference Coverage on VuMedi

A Multi-Institution Analysis of Relapsed Lymphoma Occurring During P…

Feat. F. Farooq
07:23
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monothera…

Feat. A. Herrera
24:07
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights: CAR-T as 2L Therapy in R/R Aggressive NHL

Feat. N. Ahmed
12:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety and Efficacy of CD37-Targeting Naratux…

Feat. M. Y. Levy
14:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Outcomes & Treatment Patterns in Pts With…

Feat. J. Zurko
10:55
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on a Phase II Study of OB-VEN in Patients With HTB-F…

Feat. C. Portell
10:52
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Managing R/R DLBCL: Surveying Treatment Landscape

Feat. A. Goy
09:47
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Brexucabtagene Autoleucel for R/R MCL: Real-World…

Feat. Y. Wang
06:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Concurrent Pembrolizumab With AVD for Untreat…

Feat. R. C. Lynch
17:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Allogeneic CAR-T PBCAR0191 With Intensified Lymp…

Feat. B. Shah
10:59
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Glofitamab + R-CHOP Induces High Response Rates With Minim…

Feat. N. Ghosh
09:46
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Frontline Treatment With Pembrolizumab Followed by AVD Chem…

Feat. P. Allen
08:18
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Umbralisib + Ublituximab Combo in R/R MZL: R…

Feat. J. Chavez
10:20
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Real-World Case Studies in ctDNA

Feat. P. Blombery
06:32
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on CD30-Directed CAR T-Cells for Pediatric Patients…

Feat. G. Hucks